Article Versions Notes

Kaneto H, Kimura T, Shimoda M, Obata A, Sanada J, Fushimi Y, Nakanishi S, Mune T, Kaku K. Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β-Cell Glucose Toxicity and the Development of Arteriosclerosis: “The Earlier, the Better” in Therapy with Incretin-Based Medicine. International Journal of Molecular Sciences. 2021; 22(15):7917. https://doi.org/10.3390/ijms22157917

Kaneto, Hideaki, Tomohiko Kimura, Masashi Shimoda, Atsushi Obata, Junpei Sanada, Yoshiro Fushimi, Shuhei Nakanishi, Tomoatsu Mune, and Kohei Kaku. 2021. "Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β-Cell Glucose Toxicity and the Development of Arteriosclerosis: “The Earlier, the Better” in Therapy with Incretin-Based Medicine" International Journal of Molecular Sciences 22, no. 15: 7917. https://doi.org/10.3390/ijms22157917

Kaneto, H., Kimura, T., Shimoda, M., Obata, A., Sanada, J., Fushimi, Y., Nakanishi, S., Mune, T., & Kaku, K. (2021). Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β-Cell Glucose Toxicity and the Development of Arteriosclerosis: “The Earlier, the Better” in Therapy with Incretin-Based Medicine. International Journal of Molecular Sciences, 22(15), 7917. https://doi.org/10.3390/ijms22157917